Related references
Note: Only part of the references are listed.Truncated CXCL10 Is Associated With Failure to Achieve Spontaneous Clearance of Acute Hepatitis C Infection
Antonio Riva et al.
HEPATOLOGY (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types
Xuan Ou et al.
BLOOD (2013)
CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients
Dina Ragab et al.
CYTOKINE (2013)
In vivo regulation of chemokine activity by post-translational modification
Eva A. V. Moelants et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients
Michele Weber et al.
SCIENCE (2013)
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Sid P. Kerkar et al.
CANCER RESEARCH (2012)
Overview of the mechanisms regulating chemokine activity and availability
Anneleen Mortier et al.
IMMUNOLOGY LETTERS (2012)
Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation
E. N. Arwert et al.
ONCOGENE (2012)
Stromal Expression of CD34, α-Smooth Muscle Actin and CD26/DPPIV in Squamous Cell Carcinoma of the Skin: A Comparative Immunohistochemical Study
Ayper Kacar et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Wolf Herman Fridman et al.
CANCER RESEARCH (2011)
Effect of posttranslational processing on the in vitro and in vivo activity of chemokines
Anneleen Mortier et al.
EXPERIMENTAL CELL RESEARCH (2011)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Armanda Casrouge et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Posttranslational Modification of the NH2-terminal Region of CXCL5 by Proteases or Peptidylarginine Deiminases (PAD) Differently Affects Its Biological Activity
Anneleen Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
CD8+ T cell concentration determines their efficiency in killing cognate antigen expressing syngeneic mammalian cells in vitro and in mouse tissues
Sadna Budhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
In vivo processing of CXCL12α/SDF-1α after intravenous and subcutaneous administration to mice
Bruno Antonsson et al.
PROTEOMICS (2010)
T Cell Receptor Gene Therapy for Cancer
Thomas M. Schmitt et al.
HUMAN GENE THERAPY (2009)
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Angelica M. Santos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation
Tamara Loos et al.
BLOOD (2008)
Inhibition of CD26/dipeptidyl CCL11/eotaxin-mediated recruitment peptidase IV enhances of eosinophils in vivo
Ulf Forssmann et al.
JOURNAL OF IMMUNOLOGY (2008)
Adoptive T cell therapy for cancer in the clinic
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip® Arrays and SELDI-TOF-MS
Linda Favre-Kontula et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts
J Lee et al.
CANCER RESEARCH (2005)
Elevation of dipeptidylpeptidase IV activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: Possible prostate cancer disease marker
MJ Wilson et al.
JOURNAL OF UROLOGY (2005)
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor
R Bonecchi et al.
JOURNAL OF IMMUNOLOGY (2004)
Modulation of hematopoietic stem cell homing and engraftment by CD26
KW Christopherson et al.
SCIENCE (2004)
PT-100, a small molecule dipeptidyl peptidase inhibitorg has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism
S Adams et al.
CANCER RESEARCH (2004)
Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells
A Rot et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase
PE Van den Steen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
WW Overwijk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells
KW Christopherson et al.
BLOOD (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients
H Kajiyama et al.
ONCOLOGY (2002)
Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
P Proost et al.
BLOOD (2001)
Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family
AM Lambeir et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3
P Loetscher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Molecular characterization of dipeptidyl peptidase activity in serum -: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides
C Durinx et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Share Paper
